Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma

• Published in: Human pathology Vol. 68; pp. 87 - 91
• Main Authors: Xing, Deyin, Suryo Rahmanto, Yohan, Zeppernick, Felix, Hannibal, Charlotte G., Kjaer, Susanne K., Vang, Russell, Shih, Ie-Ming, Wang, Tian-Li
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2017; Elsevier Limited
• Subjects: Adult; Age; Aged; Aged, 80 and over; Archives & records; Baltimore; Biomarkers, Tumor - genetics; Carcinoma - genetics; Carcinoma - pathology; Cell Proliferation; Denmark; Deoxyribonucleic acid; DNA; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; GTP Phosphohydrolases - genetics; Humans; Low-grade serous carcinoma; Membrane Proteins - genetics; Middle Aged; Mutation; Mutation Rate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous - genetics; Neoplasms, Cystic, Mucinous, and Serous - pathology; NRAS mutation; Oncogenic driver; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Pathology; Patients; Phenotype; Polymerase chain reaction; Proto-Oncogene Proteins B-raf - genetics; RAS signaling; Studies; Tumors; Young Adult; NRAS mutation; Low-grade serous carcinoma; Oncogenic driver; RAS signaling; Ovarian cancer

Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate duri...